雾化特布他林联合异丙托溴铵与单用特布他林治疗需无创通气的慢性阻塞性肺疾病急性加重:随机双盲对照试验
该随机双盲对照试验纳入急诊因慢性阻塞性肺疾病急性加重需无创通气的患者,比较雾化特布他林5 mg联合异丙托溴铵0.5 mg(联合组,n=115)与单用特布他林5 mg(单药组,n=117)的效果。主要终点为开始治疗后24小时内住院率和气管插管需求。结果显示联合组住院59.8% vs 单药组65.2%(RR=1.09,95%CI 0.93–1.27,p=0.39),ICU入住32.2% vs 25.6%(RR=1.25,95%CI 1.02–1.54,p=0.27),呼吸困难评分、血气参数、生命体征改善及7天死亡率均无显著差异。作者结论认为联合异丙托溴铵未减少住院和ICU需求。
要点
- 在急诊需无创通气的慢性阻塞性肺疾病急性加重患者中,联合组住院率59.8% vs 单药组65.2%,差异未达统计学显著(RR=1.09,95%CI 0.93–1.27,p=0.39)。
- 联合组ICU入住率32.2% vs 单药组25.6%(RR=1.25,95%CI 1.02–1.54,p=0.27),两组差异未达统计学显著。
- 两组在呼吸困难评分、血气参数变化、生命体征改善及7天死亡率方面均无显著差异。
- 雾化方案为特布他林5 mg联合异丙托溴铵0.5 mg或单用特布他林5 mg,第一小时每20分钟重复一次,第一天内每4小时一次。
- 作者结论认为,在需无创通气的慢性阻塞性肺疾病急性加重患者中,联合雾化异丙托溴铵和特布他林未减少住院和ICU需求。
适用人群与场景
- 因慢性阻塞性肺疾病急性加重入住急诊且需要无创通气的患者。
- 纳入标准为急诊就诊的慢性阻塞性肺疾病急性加重需无创通气患者。
处置流程与药物剂量
- 联合组:雾化特布他林5 mg联合异丙托溴铵0.5 mg;单药组:雾化特布他林5 mg。
- 雾化给药频次:第一小时内每20分钟重复一次,第一天内每4小时一次。
研究设计与关键结果
- 研究类型:随机双盲对照试验;样本量:联合组n=115,单药组n=117;人群:急诊慢性阻塞性肺疾病急性加重需无创通气患者;干预:雾化特布他林5 mg联合异丙托溴铵0.5 mg vs 单用特布他林5 mg。
- 主要终点:住院率联合组59.8%(70例)vs 单药组65.2%(75例),RR=1.09,95%CI 0.93–1.27,p=0.39;ICU入住率联合组32.2%(37例)vs 单药组25.6%(30例),RR=1.25,95%CI 1.02–1.54,p=0.27。
- 次要终点:呼吸困难评分、血气参数变化、生命体征改善及7天死亡率两组均无显著差异。
证据类型、等级与局限
- 证据类型:随机双盲对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急诊慢性阻塞性肺疾病急性加重需无创通气的患者,联合雾化异丙托溴铵与特布他林未显示比单用特布他林降低住院率或ICU入住需求。
- 作者结论认为联合雾化异丙托溴铵和特布他林未减少住院和ICU需求。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Short-acting β2 -agonists are the mainstay of treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in the emergency department (ED). It is still unclear whether the addition of short-acting anticholinergics is clinically more effective care compared to treatment with β2 -agonists alone in patients with hypercapnic AECOPD.
OBJECTIVE: The objective was to evaluate whether combining ipratropium bromide (IB) to terbutaline reduces hospital and intensive care unit (ICU) admission rates compared to terbutaline alone in AECOPD hypercapnic patients.
METHODS: In this double-blind controlled trial, patients who were admitted to the ED for AECOPD requiring noninvasive ventilation (NIV) were randomized to receive either 5 mg of nebulized terbutaline combined to 0.5 mg of IB (terbutaline/IB group, n = 115) or 5 mg of terbutaline sulfate (terbutaline group, n = 117). Nebulization was repeated every 20 minutes for the first hour and every 4 hours within the first day. Primary outcomes were the rate of hospital admission and need for endotracheal intubation within the first 24 hours of the start of the experimental treatment. Secondary outcomes included changes from baseline of dyspnea, physiologic variables, length of hospital stay, ICU admission rate, and 7-day mortality.
RESULTS: The two groups were similar regarding baseline demographic and clinical characteristics. Hospital admission was observed in 70 patients (59.8%) in the terbutaline/IB group and in 75 patients (65.2%) in the terbutaline group (respiratory rate [RR] = 1.09, 95% confidence interval [CI] = 0.93 to 1.27, p = 0.39). ICU admission was required in 37 (32.2%) patients in the terbutaline/IB group and 30 patients (25.6%) in terbutaline group (RR = 1.25, 95% CI = 1.02 to 1.54, p = 0.27). There were no significant differences in dyspnea score, blood gas parameters changes, vital signs improvement, and 7-day death rate between both groups.
CONCLUSION: In patients admitted to the ED for AECOPD requiring NIV, combination of nebulized IB and terbutaline did not reduce hospital admission and need to ICU care.
参考来源
- Beltaief K, Msolli MA, Zorgati A, et al. Nebulized Terbutaline and Ipratropium Bromide Versus Terbutaline Alone in Acute Exacerbation of Chronic Obstructive Pulmonary Disease Requiring Noninvasive Ventilation: A Randomized Double-blind Controlled Trial. Acad Emerg Med. 2018. PMID: 30156361. doi:10.1111/acem.13560
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。